These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32641971)

  • 21. Blockade of Toll-Like Receptors (TLR2, TLR4) Attenuates Pain and Potentiates Buprenorphine Analgesia in a Rat Neuropathic Pain Model.
    Jurga AM; Rojewska E; Piotrowska A; Makuch W; Pilat D; Przewlocka B; Mika J
    Neural Plast; 2016; 2016():5238730. PubMed ID: 26962463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptor4 as a modulator of fertilization and subsequent pre-implantation development following in vitro maturation in mice.
    Hosseini S; Dehghani-Mohammadabadi M; Ghafarri Novin M; Haji Molla Hoseini M; Arefian E; Mohammadi Yeganeh S; Salehi M
    Am J Reprod Immunol; 2017 Nov; 78(5):. PubMed ID: 28608468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    mBio; 2017 May; 8(3):. PubMed ID: 28487429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists.
    Peri F; Piazza M
    Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A High-Throughput Screening Approach To Repurpose FDA-Approved Drugs for Bactericidal Applications against Staphylococcus aureus Small-Colony Variants.
    Trombetta RP; Dunman PM; Schwarz EM; Kates SL; Awad HA
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30381352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain.
    Peng Y; Zhang X; Zhang T; Grace PM; Li H; Wang Y; Li H; Chen H; Watkins LR; Hutchinson MR; Yin H; Wang X
    Brain Behav Immun; 2019 Nov; 82():432-444. PubMed ID: 31542403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computational Approaches to Toll-Like Receptor 4 Modulation.
    Billod JM; Lacetera A; Guzmán-Caldentey J; Martín-Santamaría S
    Molecules; 2016 Jul; 21(8):. PubMed ID: 27483231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Online structure-based screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets.
    Lagarde N; Rey J; Gyulkhandanyan A; Tufféry P; Miteva MA; Villoutreix BO
    Oncotarget; 2018 Aug; 9(64):32346-32361. PubMed ID: 30190791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
    Sohraby F; Bagheri M; Aliyar M; Aryapour H
    J Mol Graph Model; 2017 Jun; 74():234-240. PubMed ID: 28458002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Downregulation of glucose-6-phosphate dehydrogenase contributes to diabetic neuropathic pain through upregulation of toll-like receptor 4 in rats.
    Sun Q; Zhang BY; Zhang PA; Hu J; Zhang HH; Xu GY
    Mol Pain; 2019; 15():1744806919838659. PubMed ID: 30838902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
    Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds.
    Huang H; Zhang G; Zhou Y; Lin C; Chen S; Lin Y; Mai S; Huang Z
    Front Chem; 2018; 6():138. PubMed ID: 29868550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study.
    Mofidifar S; Sohraby F; Bagheri M; Aryapour H
    Biogerontology; 2018 Apr; 19(2):133-143. PubMed ID: 29335817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring anti-malarial potential of FDA approved drugs: an in silico approach.
    Ramakrishnan G; Chandra N; Srinivasan N
    Malar J; 2017 Jul; 16(1):290. PubMed ID: 28720135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing of existing FDA approved drugs for Neprilysin inhibition: An
    Sankhe R; Rathi E; Manandhar S; Kumar A; Pai SRK; Kini SG; Kishore A
    J Mol Struct; 2021 Jan; 1224():129073. PubMed ID: 32834116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Robust Antibody-Antigen Complexes Prediction Generated by Combining Sequence Analyses, Mutagenesis, In Vitro Evolution, X-ray Crystallography and In Silico Docking.
    Loyau J; Didelot G; Malinge P; Ravn U; Magistrelli G; Depoisier JF; Pontini G; Poitevin Y; Kosco-Vilbois M; Fischer N; Thore S; Rousseau F
    J Mol Biol; 2015 Aug; 427(16):2647-62. PubMed ID: 26013163
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.